Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-UBE2K, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
HIP2 also known as LIG or Ubiquitin-Conjugating Enzyme E2 K (UBE2K) functions as an E2 ubiquitin-conjugating enzyme. It has a molecular mass of approximately 24 kDa. This protein plays an important role in the ubiquitination process where it transfers ubiquitin molecules to substrate proteins labeling them for degradation. HIP2 is expressed across various tissues in the human body indicating its widespread importance in cellular activities. It works alongside ubiquitin ligases (E3s) to ensure accurate tagging of proteins facilitating their removal by the proteasome.
Biological function summary
The function of HIP2 extends to protein homeostasis essential for maintaining cellular integrity. As part of the ubiquitin-proteasome system it ensures the elimination of damaged or excess proteins effectively preventing cellular stress or dysfunction. HIP2 operates within a complex that includes E1 enzymes and various E3 ligases highlighting its collaborative nature in protein turnover. The protein activity helps regulate cell cycle progression DNA repair and signal transduction ensuring normal cell function and adaptation to environmental changes.
Pathways
HIP2 is most involved in the ubiquitin-proteasome pathway and is linked to protein catabolism. It collaborates with key proteins like UBE2C and UBE2D which participate in tagging proteins for degradation. The coordination with these proteins demonstrates HIP2's role in managing protein levels in cells having implications in the cell's response to damage and stress. Additionally HIP2 intersects with pathways associated with cell cycle regulation allowing cells to maintain orderly division and prevent the accumulation of aberrant proteins.
HIP2 is significantly associated with neurodegenerative conditions and cancers. Aberrant HIP2 function can affect pathways controlled by proteins like p53 resulting in insufficient protein degradation that contributes to neuronal accumulation in disorders such as Alzheimer's disease. Moreover HIP2 dysregulation has links to oncogenic processes connecting to proteins like cyclins which are critical regulators in various cancers. Investigation into HIP2's function offers insights into potential therapeutic targets for these severe conditions with ongoing research focusing on modulating its activity to manage or prevent disease progression.
